ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Evotec To Acquire Drug Firm Renovis

September 24, 2007 | APPEARED IN VOLUME 85, ISSUE 39

The German drug discovery firm Evotec has agreed to acquire Renovis, a South San Francisco biotech company focused on pain and inflammatory disease drugs. The all-stock transaction, valued at about $152 million, is expected to create a company with three clinical drug candidates and a strong preclinical pipeline. The proposed deal follows a period of divestment for Evotec. The company sold its technologies business to PerkinElmer this year and recently announced the sale of its chemical development business to Aptuit (C&EN, Sept. 17, page 17).

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment